Our patient had advanced chronic kidney disease secondary to hypertension and diabetes with a baseline serum creatinine of 1.8 mg/dL prior to the initiation of anti-VEGF therapy (sorafenib). This evidence concerns the gene VEGFA and diabetes mellitus.